Home › NDC Lookup › RxCUI directory › RxCUI 1665503

Rolapitant 90 MG Oral Tablet — RxCUI 1665503

RxNorm drug concept · Semantic clinical drug
RxCUI 1665503 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1665503
Official nameRolapitant 90 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asrolapitant 90 MG (as 100 mg rolapitant HCl) Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Rolapitant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It helps prevent delayed nausea and vomiting after cancer chemotherapy in adults. You take it along with other anti-nausea medicines, not by itself.
  • It is a tablet taken by mouth as one dose within 2 hours before chemotherapy starts. You can take it with or without food. It is given before each cycle, at least 2 weeks apart, so...
  • Common ones include low white blood cell counts, hiccups, abdominal pain, decreased appetite, dizziness, indigestion, urinary tract infections and mouth sores. Tell your care team...
  • Yes. Do not take it with thioridazine or pimozide, because it can cause dangerous heart rhythm problems. It can also raise levels of other medicines for at least 28 days, so tell u...
📖 Read our full Rolapitant guide →

🕸️ Concept Web — How Rolapitant 90 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Rolapitant 90 MG Oral Tablet RxCUI 1665503

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Rolapitant 1665496
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Varubi 1673368
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Rolapitant Oral Tablet 1665501
    • Rolapitant Oral Product 1665499
    • Rolapitant Pill 1665500
    • Rolapitant Oral Tablet [Varubi] 1673370
    • Varubi Oral Product 1673371
    • Varubi Pill 1673372
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Rolapitant 90 MG SCDC · 1665498
  • Rolapitant Oral Tablet SCDF · 1665501
  • Rolapitant Oral Product SCDG · 1665499
  • Rolapitant Pill SCDG · 1665500

Brand-Name Concepts

  • Rolapitant 90 MG Oral Tablet [Varubi] SBD · 1673373
  • Rolapitant 90 MG [Varubi] SBDC · 1673369
  • Rolapitant Oral Tablet [Varubi] SBDF · 1673370
  • Varubi Oral Product SBDG · 1673371
  • Varubi Pill SBDG · 1673372
  • Varubi BN · 1673368

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1665503 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70720-0101-02 2 TABLET in 1 BLISTER PACK (70720-101-02) Varubi TerSera Therapeutics LLC 2019-08-06
Observed labelers: TerSera Therapeutics LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.